Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.2.823

Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis  

Yan, Jian (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Liu, Xiao-Long (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Han, Lu-Zhe (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Xiao, Gang (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Li, Ning-Lei (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Deng, Yi-Nan (Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University)
Yin, Liang-Chun (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Ling, Li-Juan (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Yu, Xiao-Yuan (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Tan, Can-Liang (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Huang, Xiao-Ping (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Liu, Li-Xin (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.2, 2015 , pp. 823-829 More about this Journal
Abstract
The aim of the present study was to investigate the expression of the transcription factor Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-${\alpha}$ in the tumor tissue of patients with invasive ductal carcinoma(IDC); in addition, we examined correlations between these markers. Two hundred and sixteen IDC patients, who were not previously been treated with chemo- or radiotherapy, were included in the study. All tumors were grade I-III. Expression of molecular markers was determined by immunohistochemical analysis on paraffin-embedded tissue sections. Follow-up data were collected for 3 months to 10 years and analyzed for tumor recurrence, survival time, and prognostic risk factors. We determined Ki-67 expression correlates with the expression of ER, PR, HER-2, EGFR, and TOP-${\alpha}$, as well as lymph node involvement, high tumor grade, lymphovascular invasion, high tumor stage, and high TNM stage in IDC. Positive Ki-67 expression was a risk factor for rapid tumor recurrence and may help tumor progression, leading to poor prognosis in IDC. Ki-67 was directly correlated with EGFR, TOP II-${\alpha}$, lymph node involvement, high tumor grade, lymphovascular invasion, high tumor stage, and high TNM stage in the hormone receptor subtypes of breast cancer. In triple negative breast cancer, Ki-67 correlated with TOP II-${\alpha}$. Expression of Ki-67 correlated with that of ER, PR, HER-2, EGFR, TOP II-${\alpha}$, and p21. In addition, the biomarker Ki-67 has a role as a prognostic factor and indicates a poor prognosis in IDC.
Keywords
Ki-67; invasive ductal breast cancer; prognosis;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Agboola AO, Banjo AA, Anunobi CC, et al (2011). Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. APMIS, 119, 844-52.   DOI
2 Agboola AO1, Banjo AA, Anunobi CC, et al (2013). Cell proliferation (KI-67) expression is associated with poorer prognosis in nigerian compared to British breast cancer women. ISRN Oncol, 11, 675-85.
3 Arshad H, Ahmad Z, Hasan SH (2010). Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev, 11, 1637-40.
4 Ashrafi M, Bathaie SZ, Abroun S (2012). High expression of Cyclin D1 and p21 in N-Nitroso-N-Methylurea-Induced breast cancer in wistar albino female rats. Cell J, 14, 193-202.
5 Bartek J, Lukas J (2007). DNA damage checkpoints: from initiation torecovery or adaptation. Curr Opin Cell Biol, 19, 238-45.   DOI
6 Bjerre C, Knoop A, Bjerre K, et al (2013). Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. Acta Oncol, 52, 82-90.   DOI
7 Cancer in Ukraine, 2008-2009 (2010): Bulletin of national cancer registry of Ukraine No.11. Kyiv. 111 p.
8 Carnero A, Beach DH (2004). Absence of p21WAF1 cooperates withc-myc in bypassing Ras-induced senescence and enhances oncogeniccooperation. Oncogene, 23, 6006-11.   DOI
9 Chan A, Conte PF, Petruzelka L, et al (2013). Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Res, 33, 2657-64.
10 Chan MS, Wang L, Felizola SJ, et al (2012). Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers. 27, 295-304.   DOI
11 Chen Y, Wang J, Wang X, et al (2013). STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer, 16, 40-9.   DOI
12 Galea GL, Meakin LB, Sugiyama T, et al (2103). Estrogen receptor $\alpha$ mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor $\beta$. J Biol Chem, 288, 9035-48   DOI
13 Dede DS, Gumuskaya B, Guler G, et al (2013). Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON, 18, 57-63.
14 Eom M, Lkhagvadorj S, Oh SS, et al (2013). ROS1 expression in invasive ductal carcinoma of the breast related to proliferation activity. Yonsei Med, 54, 650-7.   DOI
15 Ferguson NL, Bell J, Heidel R, et al (2013). Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J, 19, 22-30.   DOI   ScienceOn
16 Hanahan D (2000).Weinberg RA.The hallmarks of cancer. Cell, 100, 57-70.   DOI
17 Hendrayani SF, Al-Khalaf HH, Aboussekhra A(2013). Curcumin triggers p16-dependent senescence in active breast cancerassociated fibroblasts and suppresses their paracrine procarcinogenic effects. Neoplasia, 15, 631-40.   DOI
18 Ibrahim T, Farolfi A, Scarpi E, et al (2013). Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology, 84, 150-7.   DOI
19 Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52.   DOI   ScienceOn
20 Kamineni A, Anderson ML, White E, et al (2013). Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control, 24, 305-12.   DOI
21 Kanavaros P, Bai M, Stefanaki K, et al (2001). Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Histol Histopathol, 16, 377-86.
22 Klijin JGM (1991). Clinical parameters and symptoms for the progression to endocrine independence of breast cancer. In: mechanisms of progression to hormone-independent growth of breast and prostatic cancer. Carnfoth: The Parthenon Publishing Group, 11-9.
23 Lemieux J, Diorio C, Cote MA, et al (2013). Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res, 33, 2569-76.
24 Loehberg CR, Almstedt K, Jud SM, et al (2013). Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Res Treat. 138, 899-908.   DOI
25 Martin-Caballero J, Flores JM, Garcia-Palencia P, et al (2001). Tumorsusceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res, 61, 6234-8.
26 Meattini I1, Livi L, Saieva C, et al (2013). Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen. Clin Breast Cancer, 14, 1526-33.
27 Midura-Nowaczek K, Purwin M, Markowska A, et al (2013). Effect of short peptides containing lysine and epsilonaminocaproic acid on fibrinolytic activity of plasmin and topoisomerase II action on supercoiled DNA. Acta Pol Pharm, 70, 431-4.
28 Pathmanathan N, Balleine RL(2013). Ki67 and proliferation in breast cancer. J Clin Pathol, 66, 512-6.   DOI
29 Mrklic I, Capkun V, Pogorelic Z, et al (2013). Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas. Pathol Res Pract, 209, 296-301.   DOI
30 Mrklic I, Pogorelic Z, Capkun V, Tomic S (2013). Expression of topoisomerase II-$\alpha$ in triple negative breast cancer.Appl Immunohistochem Mol Morphol, 22, 132-41.
31 Perissinotti AJ, Lee Pierce M, Pace MB,et al(2013). The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res, 33, 2587-91.
32 Poole AJ, Heap D, Carroll RE, Tyner AL(2004). Tumor suppressor functions forthe CDK inhibitor p21 in the mouse colon. Oncogene, 23, 8128-34.   DOI
33 Ryu DW, Lee CH(2012). Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death. J Korean Surg Soc, 83, 187-95.   DOI
34 Salehi F, Agur A, Scheithauer BW, et al (2009).Ki-67 in pituitaryneoplasms: a review--part I. Neurosurgery, 65, 429-37.   DOI
35 Sherr CJ, Roberts JM(1999). CDK inhibitors: positive and negative regulatorsof G1-phase progression. Genes Dev, 13, 1501-2.   DOI
36 Sorbye SW1, Kilvaer TK, Valkov A, et al (2012). Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft TissueSarcomas. PLoS ONE, 7, 47068.   DOI
37 Synnestvedt M, Borgen E, Russnes HG, et al (2013). Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. Acta Oncol, 52, 91-101.   DOI
38 Tawfik K, Kimler BF, Davis MK, et al (2013). Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol, 44, 39-46.   DOI
39 Szelachowska J, Dziegiel P, Tarkowski R, et al (2012). Therapeutic radiation induces different changes in expression profiles of metallothionein (MT) mRNA, MT protein, Ki 67 and minichromosome maintenance protein 3 in human rectal adenocarcinoma. Anticancer Res, 32, 5291-7.
40 Tarhan MO, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev. 14, 1725-9.   DOI   ScienceOn
41 Thor AD, Liu S, Moore DH, et al (2000). p (21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat, 61, 33-43.   DOI
42 Xiong Y, Hannon GJ, Zhang H, et al (1993). p21 is a universal inhibitor ofcyclin kinases. Nature, 366, 701-4.   DOI
43 Yang W, Velcich A, Lozonschi I, et al (2005). Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice. Am J Pathol, 166, 1239-46.   DOI